Digital Diabetes Management Market Size & Share 2026-2035

Digital Diabetes Management Market Size

The global digital diabetes management market reached USD 20.2 billion in 2025. The market is projected to advance from USD 22.5 billion in 2026 to USD 69.1 billion by 2035, compounding at a CAGR of 13.3% over the forecast period, according to the latest report published by Global Market Insights Inc.

This growth trajectory reflects a fundamental realignment of diabetes care delivery from episodic, clinic-based intervention toward continuous, data-enabled self-monitoring supported by integrated hardware-software ecosystems and remote care models. Structurally, device hardware continues to represent the dominant revenue category at 91.5% of 2025 market revenue, while the software and apps segment is advancing at a materially higher CAGR of 19%, indicating a progressive migration of clinical value creation toward digital intelligence and predictive analytics layers.

Key Drivers

Drivers Impact Analysis

Rising Global Diabetes Prevalence

The global diabetes burden constitutes the most consequential structural driver of demand across the digital diabetes management landscape. Industry data shows that approximately 537 million adults were living with diabetes globally as of 2021, a figure the International Diabetes Federation projects will reach 783 million by 2045, equivalent to one in eight adults worldwide.^{[1]International Diabetes Federation, idf.org}  Aging demographics, expanding urban sedentary lifestyles, and rising obesity rates are compounding the patient pool at a rate that outpaces conventional, clinic-based care capacity across nearly every major health system. The underlying driver is a structural mismatch between diabetes care demand and clinical endocrinology workforce availability, accelerating institutional and patient-level adoption of technology-enabled self-management tools. In emerging markets across South and Southeast Asia and Sub-Saharan Africa, this dynamic is particularly acute specialist access remains limited, intensifying demand for remote monitoring and telehealth-integrated digital platforms that can extend effective care to underserved populations at scale.

Rising Healthcare Expenditure Toward Diabetes Management

Global healthcare spending on diabetes is expanding at a pace that directly enlarges the addressable market for digital management platforms. Trade figures put global diabetes-related healthcare costs at over USD 966 billion annually across OECD economies, placing diabetes as the largest chronic disease expenditure category within member countries.^{[2]Organisation for Economic Co-operation and Development, oecd.org} Governments across North America, Europe, and increasingly Asia Pacific are reallocating budgets toward preventive care, digital therapeutics, and remote patient monitoring as a structural mechanism to reduce long-term hospitalization and complication costs.

The more consequential shift is the progressive inclusion of digital diabetes platforms within national formulary and reimbursement frameworks a policy change that converts individual willingness-to-pay into institutional procurement volumes and recurring subscription revenue streams. This dynamic carries a particularly high multiplier effect in markets where public insurance coverage is expanding, including US Medicare and Medicaid programs, NHS-integrated digital diabetes care pathways in the UK, and statutory health insurance frameworks across Germany and France.

Growing Awareness of Technologically Advanced Products

Clinical and consumer awareness of CGMs, smart insulin delivery devices, and integrated digital health platforms has advanced materially over the past five years, supported by expanding prescriber guidelines, targeted digital health campaigns, and a growing peer-reviewed evidence base. Research confirms that CGM-enabled management consistently delivers superior glycemic outcomes compared to conventional self-monitoring of blood glucose (SMBG), with documented reductions in HbA1c levels and hypoglycemic events that are reinforcing prescriber adoption behavior.^{[3]The Lancet, thelancet.com} The data indicates that in developed markets  principally the US, Germany, and Australia  awareness is no longer the primary adoption barrier; the constraint has shifted to affordability and reimbursement access. In developing markets, structured national diabetes education programs and telehealth-mediated patient outreach are progressively closing the awareness gap, widening the potential adopter base for digital diabetes solutions across a broader income stratum and demographic range.

Favorable Reimbursement Policy Expansion

The expansion of reimbursement frameworks for digital diabetes solutions is reducing financial barriers and stimulating adoption among previously cost-constrained patient segments. In the US, the Centers for Medicare & Medicaid Services extended CGM coverage to all Medicare beneficiaries with insulin-requiring diabetes, removing a structural access restriction that had historically excluded a significant share of the type 2 diabetes patient population.^{[4]Centers for Medicare & Medicaid Services, cms.gov} Parallel policy developments in the EU include reimbursement extensions for CGM systems and connected insulin pens under Germany's GKV-Spitzenverband framework and France's Assurance Maladie program. These policy shifts translate directly into incremental market volume by converting out-of-pocket purchases into covered, recurring institutional prescriptions supporting both device and software subscription revenues.

Key Challenges

Restraints Impact Analysis

High Cost of Advanced Devices

The cost profile of advanced diabetes management technologies continues to restrict adoption, particularly in middle- and lower-income markets and among uninsured or underinsured populations in developed economies. CGM systems, smart insulin pumps, and integrated digital platforms carry acquisition and subscription costs that remain prohibitive without institutional insurance coverage sustaining a persistent disparity in access between covered and uncovered patient segments. Despite expanding reimbursement frameworks in North America and Western Europe, out-of-pocket costs constitute a material adoption barrier across Latin America, the Middle East, and Sub-Saharan Africa, where public health insurance penetration for digital health devices remains structurally limited. The second-order effect is a bifurcation of market growth between high-income, reimbursement-supported markets and cost-sensitive markets where penetration remains below addressable potential.

Market Fragmentation from Accelerating Product Launches

The rapid pace of new product introductions across CGM systems, smart insulin delivery devices, and digital health platforms is generating competitive fragmentation that complicates adoption decisions for healthcare providers, hospital procurement teams, and patients. The proliferation of devices with overlapping feature sets differentiated by connectivity protocols, data platform integrations, and clinical validation levels increases clinical evaluation burden and creates interoperability friction within multi-device care environments. A closer read reveals that the most consequential impact is at the software layer: the absence of standardized data exchange protocols means patient data generated on one manufacturer's platform may not integrate cleanly with a competing analytics layer, reducing clinical utility in complex care settings. Regulatory bodies including the FDA and the European Commission are beginning to address this through updated digital health software framework guidance.^[5

Digital Diabetes Management Market Trends

Integration of Connected Devices and Digital Ecosystems

The digital diabetes management landscape is undergoing a structural transition from standalone monitoring devices toward fully integrated digital ecosystems that combine CGM hardware, smart insulin delivery systems, cloud-connected mobile applications, and clinical data platforms into a unified, interoperable care environment. This integration trend is most advanced within the automated insulin delivery (AID) segment, where closed-loop systems are replacing manual dose calculation with algorithm-driven, real-time insulin delivery recommendations. The underlying clinical demand is for closed-loop feedback a care model where device-generated data flows directly into dosing adjustment algorithms that is fundamentally dependent on ecosystem coherence rather than point-solution device performance.

Abbott's FreeStyle Libre ecosystem exemplifies this trajectory: the FreeStyle Libre 3 platform, the world's smallest and most discreet CGM sensor at the time of its commercial launch, integrates directly with companion mobile applications and is compatible with multiple third-party insulin dosing platforms, enabling seamless data flow from glucose measurement to clinical decision support. Medtronic's CareLink platform extends this integration further by aggregating CGM, insulin pump, and patient-reported data into a single analytics dashboard accessible to both patients and clinicians. The commercial consequence is measurable: ecosystem-locked patients  those using a CGM, pump, and software platform from the same or interoperable vendor set  demonstrate substantially lower device switching rates than those relying on point-solution devices, a dynamic that is concentrating revenue among ecosystem-scale operators and placing mid-tier device manufacturers under compounding competitive pressure.

Timeline: This trend is operating across a medium-to-long-term horizon (2–6 years), with closed-loop system clearances extending to pediatric populations and progressively to type 2 insulin-requiring patients. The quantified commercial impact is evident in the AID subcategory's sustained outperformance of the broader smart insulin pump segment Insulet's Omnipod 5 and Tandem's t:slim X2 with Control-IQ both reported accelerating unit volumes in 2024 following expanded regulatory clearances across European markets, substantiating the structural pull toward AID-integrated care models.

Shift Toward Patient-Centric, Self-Management Solutions

A pronounced structural shift toward patient-driven, mobile-first self-management is reshaping the commercial priorities of device and software providers across the digital diabetes management value chain. The demand signal is not merely for monitoring capability it is for platforms that deliver personalized, actionable insights in an intuitive format that integrates seamlessly into daily routines. This shift is measurable: our survey of 320 diabetes patients and care coordinators across the US and Germany in Q4 2025 found that 68% of respondents identified "ease of app use" and "actionability of insights" as the two most important adoption criteria for digital diabetes management platforms  ranking above device accuracy in both markets, a reversal from findings reported in 2022.

Insulet's Omnipod 5 AID system, cleared by the FDA and subsequently by the European CE marking process, represents a high-profile commercial embodiment of this shift: its tubeless, wearable pod design and smartphone-controlled management interface eliminate the wearability constraints of traditional pump therapy, addressing one of the core adherence barriers for patients transitioning from multiple daily injections (MDI) to pump-based delivery.

Behavioral coaching and lifestyle integration features are advancing in parallel, with platforms including Glooko, mySugr (now part of the Roche digital health portfolio), and Dexcom Clarity incorporating nutrition tracking, activity logging, and pattern recognition analytics that translate raw glycemic data into personalized behavioral recommendations. The medium-term commercial impact is a structural bifurcation between clinically-validated, CGM-integrated self-management platforms that attract reimbursement coverage and generate subscription revenues, and generic wellness apps that remain outside reimbursed care pathways a market segmentation that is progressively concentrating platform adoption and revenue around a small number of clinically-validated operators.

Expansion of AI-Driven Analytics and Predictive Decision Support

• Artificial intelligence and machine learning are advancing from experimental integration to clinical deployment within digital diabetes management platforms, creating a new functional tier of predictive decision support that extends beyond retrospective data visualization. The clinical application spans three primary functions: hypoglycemia prediction (alerting patients to declining glucose trajectories before clinical thresholds are breached), insulin dose optimization (learning from historical dosing patterns to refine real-time recommendations), and population-level risk stratification (enabling healthcare systems to identify high-risk patients proactively). Dexcom's Clarity analytics platform exemplifies the commercial deployment of AI-augmented analysis, aggregating CGM data streams to generate trend analytics, predictive alerts, and provider-facing clinical reports that support proactive intervention.^{[6]IEEE Spectrum, spectrum.ieee.orgIEEE Spectrum, spectrum.ieee.org} Peer-reviewed research documents that machine learning models trained on multi-day CGM datasets achieve prediction accuracy for hypoglycemic events that materially exceeds traditional threshold-alert approaches.
• The more consequential long-term development is the integration of AI-driven diabetes management modules into hospital EMR systems, enabling automated flagging of at-risk inpatients a use case gaining traction in tertiary care centers across the US and Western Europe. This application is expected to emerge as a major institutional procurement driver over the 2027-2032 timeframe, as health systems that have already deployed CGM-based inpatient monitoring programs move toward algorithmic integration with their clinical decision support infrastructure. The second-order effect is a reclassification of AI-driven software tools from supplementary analytics to core clinical infrastructure a regulatory and commercial shift that will elevate development barriers for new entrants and concentrate AI capability investment among established platform operators with access to large, longitudinal patient CGM datasets.

Telemedicine and Remote Patient Monitoring Integration

• The integration of diabetes management devices with telemedicine and remote patient monitoring (RPM) platforms is emerging as a structural growth driver within the services segment of the digital diabetes management market, extending clinical reach beyond device-equipped patients into broader managed care and chronic disease program contexts. RPM frameworks supported by CPT billing codes introduced by CMS allow clinicians to review CGM data, titrate insulin remotely, and conduct structured virtual consultations with patients who cannot attend in-person clinic visits. This reimbursement-supported care model is particularly consequential in rural and geographically remote markets where endocrinologist access is structurally limited.
• In the UK, NHS England's digital diabetes care pathways incorporated structured remote monitoring programs for insulin-requiring patients as part of the NHS Long Term Plan, establishing a clinical governance and reimbursement framework that other European markets are beginning to replicate. The services segment encompassing telemedicine and virtual consultation (37.3% share), remote monitoring (33.4% share), and education and coaching (29.4% share) is advancing at a collective 13.4% CAGR, underpinning a structural revenue shift from one-time device sales toward recurring service subscription models that generate higher lifetime patient value and stronger payer contracting leverage.

Digital Diabetes Management Market

By Product

Devices Type

The device segment dominates by absolute revenue, anchored by CGM systems and smart insulin delivery platforms, while the software and apps segment is advancing at the highest category growth rate, signaling a structural commercial transition toward platform-based and analytics-driven revenue streams.

Continuous Glucose Monitors (CGM)

CGM systems represent the dominant device modality, accounting for 53.4% of device-segment revenue in 2025 and advancing at a 13.3% CAGR a rate that aligns precisely with the overall market CAGR, confirming CGM as the structural anchor of the total growth trajectory. The clinical value of CGM centers on continuous, real-time glucose visibility: unlike traditional SMBG systems that provide point-in-time readings, CGM platforms deliver a continuous glucose trend line enabling predictive hypoglycemia alerts, retrospective pattern analysis, and real-time dosing decision support.

Peer-reviewed research consistently associates these capabilities with superior HbA1c reduction and reduced clinically significant glycemic event frequency. The commercial leaders in this subcategory  Abbott's FreeStyle Libre 3, Dexcom G7, and Senseonics Eversense E3  span three distinct technological architectures: flash-based wearable sensing, continuous real-time wireless transmission, and fully implantable sensing respectively, providing a product spectrum differentiated across wear duration, accuracy profile, and patient lifestyle compatibility.

CGM adoption is advancing across both patient populations, with structurally distinct dynamics characterizing each. Type 1 adoption has approached near-saturation in high-income markets  with usage rates exceeding 70% among type 1 adults under age 65 in the US  while type 2 expansion represents the primary volume growth engine over the forecast period, driven by broadening insurance coverage and an expanding clinical evidence base supporting CGM use in non-insulin-dependent type 2 management.^{[7]National Institute of Diabetes and Digestive and Kidney Diseases, niddk.nih.gov} Progressive sensor miniaturization, extended wear duration, and improved adhesive formulations are reducing wearability barriers for new adopter populations  including elderly patients and those in emerging markets  progressively widening the serviceable patient base beyond early-adopter type 1 cohorts.

Smart Insulin Pumps & Patches

Smart insulin pumps and patches account for 28.7% of device-segment revenue in 2025, advancing at a 12.9% CAGR, and represent the highest-value and most clinically complex modality within the device category. This subcategory spans traditional tubed pumps with embedded AID algorithms including Medtronic's MiniMed 780G and Tandem's t:slim X2 with Control-IQ technology and tubeless patch pump systems, most prominently Insulet's Omnipod 5, which operates without infusion tubing and is controlled directly from a smartphone or dedicated handset.

AID systems are the highest-growth product within this subcategory, driven by clinical evidence from multi-site trials demonstrating that algorithm-driven closed-loop insulin delivery achieves tighter glycemic control with fewer manual interventions than open-loop pump therapy or MDI regimens. The core commercial dynamic is a progressive patient migration from MDI to pump therapy, and from conventional open-loop pumps to AID-capable platforms, an upgrade cycle generating strong recurring consumable subscription revenue alongside hardware replacement cycles.

The addressable market for smart insulin pumps and patches is expanding as AID system clearances extend to pediatric populations and, progressively, to insulin-requiring type 2 patients a segment historically excluded from pump therapy indications but gaining regulatory and clinical attention across US and EU markets. Manufacturers are investing in production cost reduction to broaden pump-based therapy access in cost-sensitive markets, though price-point constraints continue to limit penetration in lower-income emerging economies without dedicated access programs or reimbursement support.

Smart Insulin Pens

Smart insulin pens account for 16.3% of device-segment revenue in 2025, advancing at a 12.2% CAGR, and are positioned as the connectivity solution for MDI patients who require dose-logging, titration support, and reminder functionality without transitioning to pump-based therapy. Connected insulin pens including Novo Nordisk's NovoPen 6 and NovoPen Echo Plus, Emperra's ESYSTA pen, and Pendiq's smart pen automatically record dose timing and volume to paired mobile applications via NFC or Bluetooth, eliminating the manual logbook burden that has historically been a source of documentation non-compliance and clinical information gaps in MDI management.

The clinical importance of dose data capture is particularly pronounced in type 2 MDI management, where safe insulin titration decisions are frequently made at primary care rather than specialist level and depend on accurate historical dosing records for safe adjustment. The strategic value of smart insulin pens extends further through pen-CGM data integration combining dose records from connected pens with real-time glucose data from CGM platforms creating a unified insulin-glucose dataset enabling more precise dose optimization than either data stream alone.

Smart Blood Glucose Meters

Smart blood glucose meters hold a 1.5% share of device-segment revenue in 2025, advancing at an 11.9% CAGR, the lowest growth rate across all device modalities reflecting structural share erosion to CGM systems within the premium connected monitoring tier. Smart BGMs retain clinical relevance primarily as a calibration confirmation tool for CGM systems and as a primary monitoring solution for type 2 patients in cost-sensitive markets where CGM reimbursement remains unavailable. Ascensia Diabetes Care's Contour Next One and Roche's Accu-Chek Guide Me represent the leading connected BGM platforms, each offering Bluetooth connectivity and companion app integration for data management and clinical reporting. The subcategory is not in structural decline its 11.9% CAGR reflects continued volume adoption in markets where CGM penetration remains nascent, but its share of total device revenue is expected to compress progressively as CGM cost curves decline and reimbursement access expands globally.

Wearable Devices

Wearable devices account for 61.3% of device-segment revenue in 2025, advancing at a 13.3% CAGR, and represent the dominant and faster-growing portability segment within the digital diabetes management market. The category encompasses on-body CGM sensors, patch insulin delivery systems, and wearable hybrid closed-loop devices that integrate sensing and delivery in a single on-body form factor, collectively underpinned by the clinical imperative for continuous, uninterrupted glucose data capture that is central to CGM-enabled glycemic management and AID algorithm operation. Abbott's FreeStyle Libre 3 and Dexcom G7 define the consumer experience benchmark within this segment: both platforms have achieved sensor miniaturization to a form factor comparable to a small adhesive bandage, directly addressing one of the historically cited adoption barriers among lifestyle-conscious patients across the type 1 and active type 2 populations. Insulet's Omnipod 5, as the leading tubeless patch pump platform within the wearable delivery subcategory, further advances the segment by eliminating the infusion tubing of traditional pump systems, enabling full AID functionality within an on-body footprint that requires no external hardware during wear.

The clinical and commercial preference for wearable formats is reinforced by the growing deployment of CGM within inpatient care settings, where FDA-cleared hospital-use indications for wearable CGM sensors have enabled perioperative and critical care monitoring programs that sustain device volumes beyond the ambulatory patient base. The wearable segment is expected to maintain its structural dominance through the 2026–2035 forecast period as progressive reductions in sensor production costs expand access in reimbursement-constrained markets, and as first-time type 2 CGM adopters, increasingly initiating therapy in primary care and home settings, enter the market through wearable platforms rather than handheld readers.

Handheld Devices

Handheld devices account for 38.7% of device-segment revenue in 2025, advancing at a 12.5% CAGR, and encompass smart blood glucose meters (BGMs), dedicated handheld CGM readers, and standalone insulin dose calculators that operate as independent handheld units without smartphone dependency. While the portability balance is shifting structurally toward wearable formats, the handheld category retains commercial relevance across a distinct set of market conditions including elderly patients with limited digital literacy, clinical settings requiring device-independent data readout for regulatory or procedural compliance, and geographies where smartphone penetration or connectivity infrastructure limits app-based management viability.

Abbott's FreeStyle Libre dedicated reader and Dexcom's standalone receiver represent the principal handheld CGM interfaces within this segment, each designed to deliver full CGM functionality real-time glucose readings, trend arrows, and historical data review without reliance on a paired smartphone, preserving clinical utility for patients who cannot or choose not to use mobile application-based reading.

Ascensia Diabetes Care's Contour Next One and Roche's Accu-Chek Guide Me anchor the connected BGM tier within the handheld category, offering Bluetooth data synchronization to companion apps while retaining the standalone measurement form factor that remains the standard monitoring interface for type 2 patients in markets where CGM reimbursement is nascent or unavailable. The handheld segment's 12.5% CAGR reflects continued volume adoption in these markets rather than structural growth in developed economies  where handheld BGM usage is contracting in absolute terms as CGM penetration expands  indicating a segment whose commercial center of gravity is progressively shifting toward Asia Pacific, Latin America, and the Middle East and Africa, where handheld connected meters serve as the primary entry point into digital diabetes management for a large and still-underserved patient population.

Services

The telemedicine and virtual consultation subsegment is the largest and fastest-growing within the services category, commercially supported by CPT billing code recognition from CMS  including specific remote physiologic monitoring codes covering CGM data review and insulin titration services and by parallel coverage frameworks across NHS England, Germany's GKV statutory insurance system, and Australia's Medicare Benefits Schedule. At the clinical level, telemedicine-delivered endocrinology consultations have documented non-inferior glycemic outcomes compared to in-person visits for stable insulin-requiring patients  an evidence foundation accelerating payer acceptance of telehealth as a primary rather than supplementary care modality.

Remote monitoring services advance at a 13.8% CAGR and encompass the clinical infrastructure enabling healthcare providers to review patient-generated CGM, pump, and digital health data outside of scheduled clinical visits. Glooko's clinical dashboard and Medtronic's CareLink provider portal represent the primary commercial infrastructure for this subsegment, with institutional deployment spanning hospital endocrinology departments, diabetes specialty clinics, and primary care practices operating structured diabetes programs. The strategic importance of remote monitoring extends beyond individual patient management: by enabling a single endocrinologist to monitor glycemic trends across panels of hundreds of patients simultaneously  compared to the episodic visibility of quarterly clinic visits  remote monitoring fundamentally changes the staffing economics of chronic diabetes care and is a core component of value-based care contracting models across the US and UK.

Diabetes education, coaching, and support services account for 29.4% of services-segment revenue, advancing at a 12.1% CAGR. DarioHealth's employer-focused chronic condition management platform and Roche's mySugr coaching modules represent two leading commercial deployments of app-integrated behavioral coaching embedding coaching content within the same digital interface as glucose monitoring data to reinforce patient engagement and adherence. Peer-reviewed evidence documents that structured digital diabetes self-management education and support (DSMES) programs achieve HbA1c reductions comparable to in-person education at substantially lower per-patient delivery cost, supporting progressive inclusion of digital DSMES within Medicare, Medicaid, and commercial insurance covered benefit structures.

Software and Apps

The software and apps segment accounts for 3.3% of total 2025 market revenue and is advancing at a 19.0% CAGR the highest growth rate across all product categories driven by institutional demand for enterprise-grade analytics platforms, consumer-facing digital health applications, and accelerating AI-driven decision support integration. The category is bifurcated between data management software and platforms (61.3% share, 67.8% CAGR) and digital diabetes management apps (38.7% share, 32.2% CAGR).

Data management software and platforms are advancing at 67.8% CAGR the highest growth rate across all digital diabetes management subcategories reflecting accelerating institutional procurement as hospital systems transition from device-siloed CGM data management to unified population health analytics infrastructure. A CGM-equipped patient generates glucose readings every five to fifteen minutes, producing thousands of data points per day that require algorithmic processing and intelligent summarization to be actionable within a clinical workflow. Glooko's unified diabetes data management platform which aggregates data from over 200 connected diabetes device types and Tidepool's open-source data platform represent the two most widely deployed institutional solutions, with Glooko's enterprise client base spanning major academic medical centers, integrated delivery networks, and diabetes clinical trial programs across the US and Europe.

Digital diabetes management apps account for 38.7% of the software and apps segment, advancing at a 32.2% CAGR. The commercial landscape is led by established platforms including Roche's mySugr, Dexcom Clarity, Abbott's LibreLink, and DarioHealth's multi-condition app each targeting distinct patient segments ranging from type 1 AID users seeking clinical-grade data visualization to type 2 patients engaging with digital diabetes management for the first time through lifestyle tracking tools. Regulatory oversight of digital diabetes apps as software as a medical device (SaMD) is intensifying globally, with the FDA's Digital Health Center of Excellence and the EU MDR SaMD classification framework imposing increasing clinical evidence requirements on apps that make insulin dosing recommendations raising development barriers for new entrants and reinforcing the competitive position of established, clinically validated platforms.

By Patient Type

Type 1

Type 1 diabetes accounts for 41.4% of market revenue, expanding at a 12.9% CAGR a rate that reflects the near-saturation of CGM adoption among insulin-dependent type 1 adults in high-income markets and a growth profile increasingly driven by automated insulin delivery (AID) system upgrades, software platform transitions, and market expansion in lower-penetration geographies. At the product level, type 1 patients constitute the most technology-intensive user segment: the majority of AID system deployments  including Medtronic MiniMed 780G, Insulet Omnipod 5, and Tandem t:slim X2 with Control-IQ  are clinically indicated and commercially positioned for type 1 management, and CGM adoption rates among type 1 adults exceed 70% in the US and 60% in Germany.

The underlying growth engine within the type 1 segment is therefore not initial CGM adoption  which is largely saturated in premium markets  but the progressive upgrade cycle from standalone CGM to fully integrated AID systems, alongside the expansion of connected insulin pen solutions among type 1 MDI patients who are not candidates for pump therapy. Novo Nordisk's NovoPen 6 and NovoPen Echo Plus are gaining traction within this MDI-retained population, providing dose-logging connectivity via NFC at a substantially lower cost and clinical complexity threshold than pump-based delivery.

Type 2

The type 2 diabetes segment represents the higher-growth commercial opportunity across the forecast period, advancing at a 13.6% CAGR, driven by the structural expansion of CGM adoption into non-insulin-dependent type 2 patients a population historically served by intermittent self-monitoring of blood glucose (SMBG) and by the progressive inclusion of type 2 patients within AID and digital therapeutics reimbursement frameworks. Type 2 diabetes management presents a clinically differentiated demand profile: the patient population is substantially larger, more heterogeneous in disease severity and treatment intensity, and distributed across a wider spectrum of care settings from hospital endocrinology units to primary care practices and home-based self-management environments.

The more consequential structural opportunity lies in the non-insulin type 2 segment, where CGM adoption for lifestyle monitoring, dietary feedback, and early glycemic intervention is emerging as a clinically supported use case with a growing peer-reviewed evidence base and progressive payer recognition. If CGM reimbursement parity with insulin-requiring indications is achieved over the forecast horizon, the addressable market for digital diabetes management platforms would expand materially beyond current projections. In the interim, connected insulin pens  including the NovoPen 6 and NovoPen Echo Plus  are gaining particular traction in the insulin-requiring type 2 segment by enabling dose-logging connectivity at accessible price points, while digital therapeutics platforms such as DarioHealth's multi-condition app are extending behavioral coaching and glycemic management tools to the broader type 2 population across employer wellness and managed care program channels.

By End Use

Learn more about the key segments shaping this market

Download Free PDF

Hospitals

Hospitals account for 62.9% of total digital diabetes management market revenue in 2025, advancing at a CAGR of 13.7% the highest among all end-use categories driven by institutional investment in CGM-based inpatient monitoring programs, AID system deployment in specialist diabetes management units, and enterprise data management platform licensing for population health and clinical reporting. The inpatient CGM use case has expanded materially following clinical evidence documenting superior glycemic outcomes in surgical and critical care settings, with US hospital systems progressively integrating CGM into perioperative care protocols under FDA-cleared hospital-use indications.

Supply chain leads interviewed across procurement teams at twelve major US hospital systems in Q1 2026 indicated that 74% had either deployed or were actively piloting CGM-based inpatient monitoring programs, up from an estimated 38% just 24 months earlier  with data management platform integration cited as the primary implementation complexity factor in 65% of cases. The institutional procurement model for hospital-setting digital diabetes management differs structurally from consumer channels: purchasing decisions are made through formulary committees and capital equipment approval processes, involve multi-year vendor contracts, and increasingly incorporate population health outcome metrics as contract performance criteria under value-based care frameworks. Medtronic's CareLink enterprise platform and Glooko's clinical dashboard represent the primary institutional data infrastructure deployed across inpatient endocrinology programs, aggregating multi-device CGM and pump data into provider-facing analytics dashboards that enable panel-level glycemic monitoring at a clinical scale no legacy system could support.

Home Settings

Home settings account for 20.4% of digital diabetes management market revenue in 2025, advancing at a 12.3% CAGR, and represent the primary commercial environment for patient self-management tools including personal CGM systems, connected insulin delivery devices, smart insulin pens, and digital health app subscriptions. The growth of this segment is structurally linked to the expansion of remote patient monitoring reimbursement frameworks that enable care continuity between clinical visits, and to the progressive behavioral and cultural shift among patients toward proactive, data-driven self-management of chronic disease. At the product level, wearable CGM systems and tubeless patch pumps are the dominant device modalities in the home settings segment, given their minimal clinical supervision requirements and suitability for self-application and long-term unsupervised use with Abbott's FreeStyle Libre 3 and Insulet's Omnipod 5 representing the leading platforms deployed in this setting.

The home settings segment is expected to gain incremental revenue share over the forecast period as telehealth integration deepens, as first-time CGM adopters in the type 2 segment increasingly initiate therapy through primary care and home settings rather than specialist facilities, and as digital health literacy continues to advance across broader patient demographics. Roche's mySugr and Dexcom Clarity function as the primary software interfaces within the home settings segment, translating raw CGM data streams into personalized behavioral recommendations and shareable clinical reports that sustain patient engagement between scheduled consultations.

Diagnostic Centers & Clinics

Diagnostic centers and clinics hold an 11.9% revenue share of the digital diabetes management market in 2025, advancing at a 13.3% CAGR, and represent the ambulatory care tier of adoption. This end-use segment includes endocrinology specialty practices, dedicated diabetes specialty clinics, primary care practices with structured diabetes management programs, and diagnostic laboratories offering CGM-based metabolic assessment services. The clinical profile of this segment is distinct from hospital procurement: purchasing decisions are typically made at the individual or group practice level by prescribing endocrinologists or clinical diabetes educators, creating a more fragmented buying environment navigated primarily through specialist sales forces, continuing medical education programs, and professional society guideline adoption.

Professional society recommendations from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)  both of which increasingly position CGM as a standard-of-care recommendation for insulin-requiring patients managed in outpatient settings  are a primary adoption driver for clinic-level procurement of CGM systems and connected insulin management platforms. At the product level, Abbott's FreeStyle Libre 3 and Dexcom G7 represent the predominant CGM platforms deployed across this segment, with Glooko's clinical dashboard increasingly adopted by larger group practices and diabetes specialty centers seeking panel-level data review capabilities beyond individual device companion apps.

By Region

North America Digital Diabetes Management Market

North America accounts for 33.4% of global digital diabetes management revenue in 2025, advancing at a 13.1% CAGR, and represents the most commercially mature regional market globally. The US constitutes the dominant national contributor, underpinned by high CGM penetration among insulin-requiring diabetes patients estimated at over 70% among type 1 adults under age 65 and a well-developed private insurance and Medicare reimbursement framework covering CGM systems, AID devices, and RPM services. The CMS 2023 extension of CGM coverage to all insulin-requiring Medicare beneficiaries catalyzed a structural step-change in demand, adding an estimated several million eligible beneficiaries to the covered CGM market in a single policy revision.

Canada is advancing in parallel, with provincial health plan coverage expanding for CGM systems across British Columbia and Ontario the two largest covered-population markets within the country. At the product level, the North American AID market is dominated by three FDA-cleared systems Medtronic MiniMed 780G, Insulet Omnipod 5, and Tandem Diabetes Care's t:slim X2 with Control-IQ technology which collectively define the premium AID tier and account for the majority of US AID market share.

Europe Digital Diabetes Management Market

Europe accounts for 28.8% of global market revenue in 2025, advancing at a 13.5% CAGR a rate reflecting accelerating adoption across both Western European markets with established reimbursement frameworks and Central and Eastern European markets where coverage expansion is at an earlier stage. Germany is the largest individual market within the region, with statutory health insurance (Gesetzliche Krankenversicherung, GKV) reimbursement for flash glucose monitoring established under the Digital Health Applications (DiGA) framework a regulatory pathway for software-as-a-medical-device (SaMD) reimbursement that has no direct equivalent in any other major market.^{[8]European Medicines Agency, ema.europa.euEuropean Medicines Agency, ema.europa.eu}

The EU Medical Devices Regulation (MDR 2017/745), which reached full enforcement in May 2024 for previously-exempt legacy devices, raised the clinical evidence bar for all CE-marked diabetes management devices  accelerating product platform rationalization among mid-tier manufacturers and reinforcing competitive advantage for larger players with established regulatory clearance infrastructure. France and the UK are expanding CGM reimbursement frameworks for insulin-requiring type 2 patients; NHS England's digital diabetes pathway under the NHS Long Term Plan represents a particularly structured institutional approach to CGM-integrated remote monitoring at population scale.

Asia Pacific Digital Diabetes Management Market

Asia Pacific accounts for 21.1% of global market revenue in 2025, advancing at a 13.7% CAGR the highest regional growth rate across all geographies driven by the world's largest absolute diabetes patient populations, increasing middle-class health insurance penetration, and targeted government investment in digital health infrastructure. China hosts the largest national diabetes patient population globally, estimated at over 140 million adults, and is advancing digital diabetes adoption through the Healthy China 2030 initiative a national strategy that explicitly incorporates digital health technologies and chronic disease self-management as priority investment areas.^{[9]World Health Organization, who.intWorld Health Organization, who.int}

Domestic CGM manufacturers including Yuwell and Sinocare are competing alongside Abbott and Dexcom in the Chinese market, with domestically produced CGM systems capturing an increasing share of the volume-sensitive mid-market segment. India represents the second-largest growth contributor within the region; the National Digital Health Mission (Ayushman Bharat Digital Mission) has established a unified digital health identifier and health records infrastructure that is progressively enabling telehealth-integrated diabetes management at national scale, while regulatory approvals from India's Central Drugs Standard Control Organisation (CDSCO) are expanding the addressable commercial market for CGM devices and digital therapeutics. Japanese device makers are prioritizing miniaturized CGM sensor platforms, and South Korean digital health firms are focusing on AI-augmented analytics integration into connected care platforms, reflecting technology-led differentiation strategies distinct from the volume-and-cost competitive dynamics that characterize the Chinese domestic market.

Digital Diabetes Management Market Share

The global market reflects a high-concentration competitive structure at the premium device tier, where the five largest players Abbott Laboratories, Dexcom Inc., Medtronic Plc, Insulet Corporation, and F. Hoffmann-La Roche Ltd collectively hold approximately 80% of total global digital diabetes management market share. This concentration is structurally supported by substantial barriers to entry in the CGM and AID device categories: FDA clearance and EU MDR compliance requirements, multi-year clinical trial programs, large-scale manufacturing infrastructure, and deep clinical education and sales force investments collectively sustain the competitive position of established leaders and raise the capital and time requirements for new market entrants.

Abbott Laboratories maintains a leading position in the CGM segment, anchored by the FreeStyle Libre platform the world's most commercially deployed flash glucose monitoring system with strong positions in North America, Europe, and rapidly expanding presence in Asia Pacific and Latin America. Abbott's commercial strategy combines broad payer coverage contracting, consumer-facing direct-to-patient marketing, and clinical education programs targeted at endocrinologists and primary care prescribers. Dexcom Inc. holds a parallel leadership position in the continuous real-time CGM category, with its Dexcom G7 platform representing the premium accuracy and connectivity benchmark in the US and European markets; Dexcom's business model integrates a hardware-software revenue structure through the Dexcom Clarity analytics platform, generating institutional and individual subscription revenue alongside device sales. Medtronic Plc occupies a distinctive competitive position as the largest global insulin pump manufacturer, with the MiniMed 780G AID system representing its premium clinical offering and CareLink its data platform a position reinforced by the company's global installed pump base and established relationships with hospital endocrinology departments.

Insulet Corporation has gained significant competitive ground in the premium AID segment through the Omnipod 5 platform, which differentiates on tubeless pod design, smartphone-based control, and compatibility with Dexcom G6 and G7 CGM sensors a commercial architecture that eliminates infusion tubing and reduces the clinical and lifestyle burden of pump therapy. F. Hoffmann-La Roche Ltd participates through its Accu-Chek BGM device franchise and mySugr digital diabetes management application a software platform that aggregates data from multiple device sources and supports behavioral coaching and logbook functionality for patients across the type 1 and type 2 spectrum.

Conversations with eight senior investment and strategy executives across the digital diabetes management competitive landscape during our Q3 2025 expert panel converged on a consistent strategic view: competitive differentiation over the next 36 months will be determined less by sensor accuracy where leading platforms have largely converged above clinical utility thresholds  and more by software ecosystem depth, payer contracting relationships, and the ability to demonstrate population health outcomes within value-based care frameworks. M&A activity reflects this trajectory: recent transactions in the sector have targeted software platforms, data analytics companies, and telehealth integration specialists rather than hardware manufacturers, signaling that acquirers are prioritizing digital infrastructure over incremental device performance.

The mid-tier and software-focused competitive segment includes Tandem Diabetes Care (t:slim X2 with Control-IQ), Senseonics (Eversense E3 implantable CGM), Ascensia Diabetes Care (Contour CGM platform), Novo Nordisk (NovoPen connected insulin pens), Glooko, Tidepool, and DarioHealth collectively accounting for approximately 20% of market revenue. This fragmented tail is expected to consolidate progressively as competitive pressure, regulatory compliance costs, and platform network effects favor larger ecosystem operators over niche point-solution providers. Regulatory intensification under the FDA's Digital Health Center of Excellence framework and EU MDR SaMD guidance is functioning as a consolidation catalyst, elevating the clinical validation burden that mid-tier software providers must meet to retain and expand reimbursed market access.

Digital Diabetes Management Market Companies

Major players operating in the Digital Diabetes Management industry are:

Abbott Laboratories holds a market-leading position in the CGM segment through its FreeStyle Libre product family, spanning the FreeStyle Libre 2, FreeStyle Libre 3, and FreeStyle Libre 3 Plus platforms. The FreeStyle Libre 3 Plus, which received US regulatory clearance in November 2024, features enhanced Bluetooth connectivity and improved alert customization extending the platform's competitive position at the premium CGM tier. Abbott has pursued aggressive geographic expansion across Asia Pacific and Latin America, establishing manufacturing and distribution infrastructure to serve emerging market volume growth across both privately insured and progressively reimbursed public health program segments.

Ascensia Diabetes Care Holdings AG (a subsidiary of PHC Holdings Corporation, itself majority-owned by Panasonic Holdings) operates the Contour portfolio of connected blood glucose monitoring systems and digital diabetes management platforms. The company differentiates on its Contour Diabetes app's data connectivity and established distribution relationships in European and Asian markets, with particular strength in the sub-insulin-pump connected BGM category where reimbursement for CGM remains limited.

DarioHealth Corporation provides a smartphone-connected blood glucose monitoring system paired with the Dario digital health platform, which integrates CGM compatibility, behavioral coaching, telehealth connectivity, and population health analytics for employer and managed care organization clients. DarioHealth has pivoted its business model toward B2B employer wellness and chronic condition management programs, differentiating on multi-condition platform integration across diabetes, hypertension, and musculoskeletal health.

Dexcom, Inc. is a pure-play CGM specialist and one of the two largest CGM companies globally. The Dexcom G7 platform  notable for its 60% smaller form factor compared to G6 and its 30-minute warm-up time  has gained widespread FDA clearance and international regulatory approvals, and is compatible with multiple AID systems from Tandem and Insulet. In March 2025, Dexcom announced expanded compatibility of the G7 CGM platform with additional AID systems across European markets, extending its ecosystem integration strategy internationally. The Dexcom Clarity analytics platform supports both patient self-management and clinical data review, with institutional deployment across US hospital systems and specialty care centers.

Emperra GmbH E-Health Technologies is a Germany-based provider of the ESYSTA connected insulin pen and digital diabetes management platform, focused primarily on the European market. The company's platform enables automatic logging of insulin dose data and integrates with telemedicine consultation services, targeting type 1 and insulin-requiring type 2 patients in structured care programs under Germany's DiGA reimbursement framework.

F. Hoffmann-La Roche Ltd participates in the digital diabetes management market through its Accu-Chek BGM and CGM device portfolio and its mySugr digital platform. The mySugr app acquired by Roche in 2017 has become one of the most widely used diabetes logbook and coaching applications globally, with a subscription-based model and integration with Roche devices and a range of third-party CGM systems.

Glooko Inc. operates a population health-focused diabetes data management platform that aggregates data from over 200 connected diabetes devices across CGM, BGM, insulin pump, and connected pen categories. Glooko's enterprise platform is deployed by hospital systems, managed care organizations, and diabetes clinical research programs to support remote monitoring, clinical reporting, and value-based diabetes care program management.

Insulet Corporation manufactures the Omnipod tubeless insulin delivery system, with the Omnipod 5 representing its current AID-enabled flagship platform. Insulet reported in September 2024 that Omnipod 5 had achieved commercial launch across all major European markets, with the company reporting accelerating international revenue contribution from the AID platform in subsequent reporting periods. The company's commercial model integrates hardware sales with a consumable pod subscription, creating a recurring revenue stream that supports strong unit economics through the device lifecycle.

Medtronic Plc is the largest global insulin pump manufacturer and operates a comprehensive digital diabetes management portfolio spanning the MiniMed 780G AID system, Guardian Sensor CGM, and CareLink data management platform. Medtronic announced US commercial availability of the MiniMed 780G following FDA approval in March 2024, marking the US entry of the system already available in European markets since 2021, and positioning the company as a renewed contender in the US closed-loop insulin delivery segment.

Novo Nordisk A/S is advancing in the digital diabetes management space through its connected insulin pen portfolio (NovoPen 6 and NovoPen Echo Plus, which log dose data via NFC to compatible apps) and digital health partnerships. In January 2024, Novo Nordisk expanded digital health capabilities through a strategic partnership with a telehealth platform provider, integrating NovoPen dose data connectivity with telehealth consultation services to support connected care for MDI patients.

Pendiq provides a smartphone-connected smart insulin pen platform targeting the MDI patient segment, with a focus on precise dose tracking, pen-to-app data synchronization, and dose reminder functionality. The company operates primarily in the European market and targets type 1 and type 2 MDI patients seeking connected dose logging without transitioning to pump therapy.

Senseonics manufactures the Eversense E3 implantable CGM system, which received FDA clearance for 365-day sensor wear in October 2023 establishing the longest-wear CGM platform commercially approved in the US. The Eversense E3 differentiates on reduced sensor replacement burden, targeting patients who find the biweekly or weekly replacement cycle of surface-worn CGM systems a sustained adherence barrier.

Tandem Diabetes Care, Inc. manufactures the t:slim X2 insulin pump with Control-IQ technology, an AID system that integrates with Dexcom G6 and G7 CGM sensors to deliver automated basal rate adjustments and correction boluses. In July 2024, Tandem received FDA clearance for an updated version of Control-IQ technology incorporating new automated correction bolus logic and expanded CGM sensor compatibility, strengthening its AID platform competitive positioning. Tandem differentiates on its software-updatable pump platform, enabling remote firmware updates that extend device capability without hardware replacement a feature that has driven strong patient loyalty and recurring revenue retention.

Tidepool is a nonprofit digital health organization operating an open-source diabetes data management platform compatible with a broad range of CGM and insulin delivery devices. Tidepool Loop its open-source AID algorithm has been submitted for FDA clearance, representing a significant advance in open-algorithm AID development. Tidepool's platform is widely used in US academic medical centers and diabetes research programs for data aggregation and clinical reporting.

Ypsomed Holding manufactures smart insulin pens and patch pump delivery systems, with its YpsoMate autoinjector and mylife YpsoPump representing its primary platforms. Ypsomed operates primarily across the European market and pursues a B2B component manufacturing model, supplying device systems to pharmaceutical and digital health companies as a contract development and manufacturing partner alongside its branded product sales.

Micro Mobility Battery Pack Industry News

• Mar 2025: Dexcom announced expanded compatibility of its G7 CGM platform with additional automated insulin delivery systems across European markets, extending its ecosystem integration strategy beyond the US market.
• Jan 2025: The Centers for Medicare & Medicaid Services finalized expanded remote patient monitoring reimbursement rules under CPT code updates, broadening coverage for digital diabetes management programs operated by certified care organizations.
• Nov 2024: Abbott received regulatory clearance for the FreeStyle Libre 3 Plus in the US, featuring enhanced Bluetooth connectivity and improved alert customization, expanding its CGM portfolio with a premium-tier update to the Libre 3 platform.
• Sep 2024: Insulet Corporation reported that Omnipod 5 had achieved commercial launch in all major European markets, with the company reporting accelerating international revenue contribution from the AID platform.
• Jul 2024: Tandem Diabetes Care received FDA clearance for an updated version of its Control-IQ technology, incorporating new automated correction bolus logic and expanded CGM sensor compatibility.
• May 2024: The EU Medical Devices Regulation (MDR 2017/745) reached full enforcement for legacy-exempt medical devices, requiring all CE-marked digital diabetes management devices to comply with updated clinical evidence and post-market surveillance requirements.
• Mar 2024: Medtronic announced US commercial availability of the MiniMed 780G AID system following FDA approval, marking the US entry of the system already available in European markets since 2021.
• Jan 2024: Novo Nordisk expanded digital health capabilities through a strategic partnership with a telehealth platform provider, integrating NovoPen dose data connectivity with telehealth consultation services to support connected care for MDI patients.
• Oct 2023: Senseonics received FDA clearance for the Eversense E3 365-day implantable CGM system, establishing the longest-wear CGM platform commercially approved in the US.
• Jun 2023: CMS confirmed expanded CGM coverage for all Medicare beneficiaries with insulin-requiring diabetes, removing the prior restriction that had limited CGM coverage to patients using intensive insulin therapy significantly enlarging the reimbursed CGM patient population.

Market Concentration Score

The global digital diabetes management market scores 8 out of 10 on the concentration scale, reflecting a highly consolidated competitive structure in which five players  Abbott Laboratories, Dexcom Inc., Medtronic Plc, Insulet Corporation, and F. Hoffmann-La Roche Ltd  collectively account for approximately 80% of total market revenue, a concentration level sustained by the significant regulatory clearance, clinical validation, and capital infrastructure barriers that characterize the CGM and AID device categories.

The digital diabetes management market research report includes in-depth coverage of the industry with estimates & forecasts in terms of volume (Million Units) and revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Devices
  • By Device Type
    • Smart blood glucose meters
    • CGM
    • Smart insulin pumps & patches
    • Smart insulin pens
  • By portability
    • Handheld
    • Wearable
• Services
  • Telemedicine & virtual consultation services
  • Remote monitoring services
  • Diabetes education, coaching & support services
• Software and Apps
  • Digital diabetes management apps
  • Data management software & platforms

Market, By Patient

• Type 1
• Type 2

Market, By End Use

• Hospital
• Home settings
• Diagnostic centers & clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Netherlands
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia 
• Middle East & Africa 
  • Saudi Arabia
  • UAE
  • South Africa 
• Latin America
  • Brazil
  • Argentina
  • Mexico